**PHS OTHER SUPPORT**

**Ensure you are using the latest form. Don’t reuse and recycle old forms.**

**For All Application Types – DO NOT SUBMIT UNLESS REQUESTED**

*There is no "form page" for reporting Other Support. Information on Other Support should be provided in the format shown below.*

**\*DISCLAIMER** – This annotated guidance document is aimed to assist you in preparing your Other Support, and provides different examples of Projects, Proposals and In-kind Contributions. The examples should help guide you in applying the NIH requirements, however, they are not absolute, nor all-inclusive. When in doubt, reach out to your Grants Associate for guidance.

\*Name of Individual: Anderson, R.R.

Commons ID: Anderson RR

**Other Support – Project/Proposal**

ACTIVE

\*Title: Chloride and Sodium Transport in Airway Epithelial Cells

Major Goals: The major goals of this project are to define the biochemistry of chloride and sodium transport in airway epithelial cells and clone the gene(s) involved in transport.

\*Status of Support: Active

Project Number: 2 R01 HL 00000 - 13

Name of PD/PI: Anderson, R.R.

\*Source of Support: NHLBI

\*Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Date: (MM/YYYY) (if available): 03/2021 – 02/2026

\* Total Award Amount (including Indirect Costs): $1,492,232

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 3.6 calendar  |
| 2. 2023  | 3.6 calendar  |
| 3. 2024 | 3.6 calendar  |
| 4. 2025 | 3.6 calendar |
| 5. 2026 | 3.6 calendar |

\*Title: Ion Transport in Lungs

Major Goals: The major goal of this project is to study chloride and sodium transport in normal and diseased lungs.

\*Status of Support: Active

Project Number: 5 R01 HL 00000-04

Name of PD/PI: Baker, J.B.

\*Source of Support: NHLBI

\*Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Date: (MM/YYYY) (if available): 04/2017 – 03/2022

\* Total Award Amount (including Indirect Costs): $981,736

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 4. 2021  | 1.2 calendar  |
| 5. 2022 | 1.2 calendar  |

\*Title: Effects of smoking on gene mutations and lungs.

Major Goals: To study the effect of smoking on gene mutations and to perform specialized genome-wide mutation analysis on a cohort of adults.

\*Status of Support: Active

Project Number: N/A

Name of PD/PI: Anderson, R.R.

\*Source of Support: JHU Discovery Award/Internal award

\*Primary Place of Performance: Johns Hopkins University, Baltimore MD

Project/Proposal Start and End Date: (MM/YYYY) (if available): 1/1/2021 – 12/31/2021

\* Total Award Amount (including Indirect Costs): $80,000

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 1.2 calendar  |

\*Title: SAMPLE COVID-19 Clinical Trial

Major Goals: Phase 2 multicenter study the evaluate the efficacy and safety of new COVID-19 vaccine on children aged 8-11

\*Status of Support: Active

Project Number/Protocol # 678910

Name of PD/PI: Jane Doe

\*Source of Support: Pfizer

\*Primary Place of Performance: Johns Hopkins University Hospital, Baltimore, MD

Project/Proposal Start and End Date: (MM/YYYY) (if available): 5/1/2021 – 4/30/2022

\* Total Award Amount (including Indirect Costs): *anticipated* $400,000 ($400 per subject enrolled)

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.12 calendar  |

\*Title: Sample of a subaward issued to JHU from another entity – use the title of the subaward

\*Major Goals: Provide a brief statement of the overall objectives of the subaward arrangement or a description of the activity. ­

\*Status of Support: Active

Project Number: U01CAXXXXXX – must be the Prime’s award # (not the subaward #)

Project Number, Name of PD/PI, and Source of Support is all for the Prime awardee (the pass-through entity)

Name of PD/PI: Shiv Roy – name of the prime awardee at the pass-through entity (PTE)

\*Source of Support: NIH/NCI

**\***Primary Place of Performance: Columbia University Irving Medical Center, New York, NY

Project/Proposal Start and End Dates: 9/1/2019 – 2/28/2024 – this should be the period of performance of the subaward, sometimes indicated as the *Estimated Period of Performance*.

\*Total Award Amount: $463,000 – the total we expect to be awarded from the pass-through entity (PTE) for the entire period of performance (project period of the subaward).

\*Person Months: Indicate months associated with JHU PI’s time on this subaward. For an active project, provide the level of actual effort in person months for the current budget period and indicate the proposed level effort for each remaining budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 3. 2022 | .2 calendar  |
| 4. 2023 | .2 calendar  |
| 5. 2024 | .2 calendar |

\*Title: **Project #1** – Impact of genetic counseling on lung cancer patients. [Sample of a component of a multi-project award issued to JHU – use the title of the ***component***].

\*Major Goals: Provide a brief statement of the overall objectives of the subproject or a description of the activity.

\*Status of Support: Active

Project Number: 2 P01CAXXXXXX-01 – must be the Prime’s award #

Name of PD/PI: Roman Roy – name of the PI of the overall award

\*Source of Support: NIH/NCI

**\***Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Dates: 10/1/2021 – 9/30/2026 – this should be the period of performance of the subproject, may or may not coincide with the overall award.

\*Total Award Amount: $750,000

\*Person Months: Indicate months associated with Columbia PI’s time on the subproject.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | .2 calendar  |
| 2. 2022 | .2 calendar  |
| 3. 2024 | .2 calendar |
| 4. 2025 | .2 calendar |
| 5. 2026 | .2 calendar |

\*Title: Analysis of Smoking & Gene Mutation Study Data of 2018

Major Goals: Consulting for a colleague at Leidos on his statistical design and analysis of a pre-existing study, with plans to co-author a paper.

\*Status of Support: Active

Project Number: XDR676867

Name of PD/PI: Kendall Roy

\*Source of Support: Leidos

\*Primary Place of Performance: Washington, DC

Project/Proposal Start and End Date: (MM/YYYY) (if available): 6/1/2021 – 5/31/2022

\* *Estimates for the amount paid/to be paid*: $10,000

PENDING

\*Title: Liposome Membrane Composition and Function

Major Goals: The major goals of this project are to define biochemical properties of liposome membrane components and maximize liposome uptake into cells.

\*Status of Support: Pending

Project Number: DCB 950000

Name of PD/PI: Anderson, R.R.

\*Source of Support: National Science Foundation

\*Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Date: (MM/YYYY) (if available): 10/2021 – 09/2023

\* Total Award Amount (including Indirect Costs): $262,921

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 2.4 calendar  |
| 2. 2023 | 2.4 calendar  |

**IN-KIND**

**General notes:**

In-kind contributions **not intended for use on the project/proposal being proposed** in this application must be reported as Other Support.

If the time commitment or dollar value is not readily ascertainable, reasonable estimates should be provided.

There is no de minimis value. Applicants and recipients may apply a “reasonable standard.” Disclosure is not expected for sources with insignificant value or material contribution.

In-kind contributions **intended for use on the project being proposed** to NIH must be included as part of the Facilities and Other Resources or Equipment section.

For in-kind resources with no associated time commitment, researchers can list zero effort, but must provide the estimated dollar value of the in-kind resource. The effort and dollar value cannot both be zero.

***Examples:***

\*Summary of In-Kind Contribution: Post-doctoral fellow, Dr. John Smith, who conducts research activities in the Anderson lab. Salary supported by Oxford University.

\*Status of Support: Active

\*Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Date (MM/YYYY) (if available):

\*Person Months (Calendar/Academic/Summer) per budget period: N/A

\*Estimated Dollar Value of In-Kind Information: $80,000

\*Summary of In-Kind Contribution: Cell line XYZ provided by Dr. Jennifer Smith at Cornell University.

\*Status of Support: Active

\*Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Date (MM/YYYY) (if available):

\*Person Months (Calendar/Academic/Summer) per budget period: N/A

\*Estimated Dollar Value of In-Kind Information: estimate $1,000

\*Summary of In-Kind Contribution: C57BL/6-*ABC1*tm1jbp mice provided by Dr. Joseph Jones at the University of Texas at Austin.

\*Status of Support: Active

\*Primary Place of Performance: Johns Hopkins University, Baltimore, MD

Project/Proposal Start and End Date (MM/YYYY) (if available):

\*Person Months (Calendar/Academic/Summer) per budget period: N/A

\*Estimated Dollar Value of In-Kind Information: estimate $4,000

\*Summary of In-Kind Contribution: Pilot study conducted by collaborator, Dr. Joe Juice at Duke University, whose experiments have benefitted Dr. RR Anderson’s research. Dr. Juice received internal seed funds to conduct a pilot study on lung cancer to collect preliminary data for a future proposal we plan to submit together. The time spent discussing the research methodology, design, and statistics have helped me with my lab’s research, in general.

\*Status of Support: Active

\*Primary Place of Performance: Duke University, Raleigh, North Carolina

Project/Proposal Start and End Date (MM/YYYY) (if available): N/A

\*Person Months (Calendar/Academic/Summer) per budget period

|  |  |
| --- | --- |
| Year (YYYY) | Person Months (##.##) |
| 1. 2022 | .10 month |

\*Estimated Dollar Value of In-Kind Information: $25,000 [amount of seed funds Dr. Juice is using for pilot study]

\*Summary of In-Kind Contribution: Office space provided by University of Madrid for my two-week visit as honorary professor during the summer

\*Status of Support: Active

\*Primary Place of Performance: Madrid, Spain

Project/Proposal Start and End Date (MM/YYYY) (if available): 6/1/2022 – 7/31/2022

\*Person Months (Calendar/Academic/Summer) per budget period

|  |  |
| --- | --- |
| Year (YYYY) | Person Months (##.##) |
| 1. 2022 | .5 summer month |

\*Estimated Dollar Value of In-Kind Information: $2,000

**\*Overlap** (summarized for each individual):

There is scientific overlap between aim 2 of NSF DCB 950000 and aim 4 of the application under consideration. If both are funded, the budgets will be adjusted appropriately in conjunction with agency staff.

I, PD/PI or other senior/key personnel, certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.

* Senior/key persons must use [DocuSign](https://cuit.columbia.edu/electronic-signature), not cut-and-paste
	+ NIH will not accept wet signatures. You cannot copy and paste a signature. You must use software that will date and timestamp the signature so it is auditable and traceable to the person signing it.
* Other Support must be signed before it is incorporated into Just-in-Time package or RPPR
* Department/PI must retain the “original” electronic signature, before it is added into the Just-in-Time PDF or RPPR

*\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*